Who must avoid it entirely in the class framing: anyone pregnant or breastfeeding, anyone with the personal/family MTC or MEN 2 history above, and anyone with prior serious hypersensitivity to a GLP-1 agonist
Final pricing will depend on approval status, insurance coverage, and any manufacturer savings programs that may become available
For obesity management , GLP-1 receptor agonists such as semaglutide 2.4mg (Wegovy) are recommended by NICE (TA875) only through specialist weight management services for people with specific BMI thresholds and weight-related complications
Its there when you need it
doi: 10.1056/NEJMoa1612917
Ongoing studies, such as the SOUL trial, are exploring the potential cardiovascular benefits of oral semaglutide in T2DM patients with established atherosclerotic cardiovascular disease and/or chronic kidney disease [50]